BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30746134)

  • 1. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.
    Hanna RM; Lopez EA; Hasnain H; Selamet U; Wilson J; Youssef PN; Akladeous N; Bunnapradist S; Gorin MB
    Clin Kidney J; 2019 Feb; 12(1):92-100. PubMed ID: 30746134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.
    Hanna RM; Tran NT; Patel SS; Hou J; Jhaveri KD; Parikh R; Selamet U; Ghobry L; Wassef O; Barsoum M; Bijol V; Kalantar-Zadeh K; Pai A; Amin A; Kupperman B; Kurtz IB
    Front Med (Lausanne); 2020; 7():579603. PubMed ID: 33117836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
    Ahmed M; Alouch N; Ahmed A; Jagadesh SK
    Proc (Bayl Univ Med Cent); 2021 Mar; 34(4):527-529. PubMed ID: 34219948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review.
    Hanna RM; Ahdoot RS; Kim MS; Jhaveri KD; Kalantar-Zadeh K; Kurtz IB
    Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):47-56. PubMed ID: 34750330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.
    Shye M; Hanna RM; Patel SS; Tram-Tran N; Hou J; Mccannel C; Khalid M; Hanna M; Abdelnour L; Kurtz I
    Clin Kidney J; 2020 Dec; 13(6):969-980. PubMed ID: 33391740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
    Hanna RM; Abdelnour L; Hasnain H; Selamet U; Kurtz I
    SAGE Open Med Case Rep; 2020; 8():2050313X20907033. PubMed ID: 32110410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
    Zhang PL; Raza S; Li W; Kanaan HD
    Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration.
    Phadke G; Hanna RM; Ferrey A; Torres EA; Singla A; Kaushal A; Kalantar-Zadeh K; Kurtz I; Jhaveri KD
    Clin Kidney J; 2021 Oct; 14(10):2158-2165. PubMed ID: 34603693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy.
    Waltl I; Zehetner C; Seifarth C; Handle F; Kieselbach GF; Angermann R; Kralinger MT
    Curr Eye Res; 2018 Mar; 43(3):368-375. PubMed ID: 29172741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.
    Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study.
    Bagheri S; Dormanesh B; Afarid M; Sagheb MM
    Galen Med J; 2018; 7():e1299. PubMed ID: 34466447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
    Touzani F; Geers C; Pozdzik A
    Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.